Mabylon starts Phase I trial for the prophylaxis of peanut allergy

(CONNECT) Mabylon AG has announced that on December 11, 2025, the first volunteer was treated with MY006 in the first human clinical trial. This is a novel and triple-acting monoclonal antibody for the prophylactic treatment of peanut allergy. This exact copy of a human antibody is intended to offer a new approach to preventing allergic reactions in people with peanut allergies.

The trispecific format of the MY0666 antibody now being investigated in the Phase I clinical trial targets three different allergy triggers simultaneously, explains Mabylon's Scientific Director Dr. Niccolò Pengo. "This improves broad neutralization compared to monospecific antibodies. It was developed for constant serum levels, high stability and continuous protection with infrequent dosing, about two to four subcutaneous injections per year." This would eliminate the limitations of current allergy therapies, which require frequent administration.

The current study is being conducted in the USA. It evaluates the safety and local tolerability of MY006 in both healthy volunteers and patients. In addition, the pharmacodynamics and clinical activity of the active substance in patients are being investigated.

"With the administration of the first dose to a participant, we are one step closer to potentially providing a prophylactic therapy that could protect patients from the risks of accidental contact with peanuts," Peter Lichtlen, Chief Medical Advisor of the company based in the Bio-Technopark Schlieren-Zurich, is quoted as saying. "We thank the clinical investigators, study centers and volunteers for their commitment to this groundbreaking study."

Mabylon received CHF 30 million from private investors as recently as August 2025. According to the information provided, the sum came primarily from former executives and members of the Board of Directors of the Roche pharmaceutical group. ce/mm